MedTrace Logo

The Effect of Probiotics on Gut Microbiotain After Helicobacter Pylori Eradication

NCT05658055 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2023-02-08

No results posted yet for this study

Summary

The purpose of this study is to evaluate the effect of probiotics during vonoprazan-amoxicillin dual therapy on the gut microbiota in Helicobacter pylori eradication and to investigate whether the eradication rate of H.pylori will be improved when adding probiotics

Conditions

  • Helicobacter Pylori Infection
  • Infections
  • Intestinal Bacteria Flora Disturbance

Interventions

DRUG

Vonoprazan

Potassium-competitive acid blocker

DRUG

Amoxicillin

Antibiotic for H. pylori eradication

DRUG

probiotics

Medilac-S; Enterococcus faecium 4.5\*10\^8 and Bacillus subtilis 5.0\*10\^7, Hanmi,Beijing, China

Sponsors & Collaborators

  • Nanjing First Hospital, Nanjing Medical University

    lead OTHER

Principal Investigators

  • Zhenyu Zhang · Nanjing First Hospital, Nanjing Medical University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-01
Primary Completion
2023-12-31
Completion
2023-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05658055 on ClinicalTrials.gov